20
KIT
(Premarket Approval Application)
for sugarBEAT® to the U.S. FDA. The
other product proBEAT combines
non-invasive glucose data processed
using artificial intelligence under
a digital healthcare subscription
service that has been piloted in the
U.S. as a general wellness product as
part of its BEAT diabetes program.
In January 2023, Nemaura
announced receipt of an initial
purchase order for 5,000 proBEAT
subscriptions from HealthFleet Inc,
a leading US telehealth provider
focusing on care, coaching, and
health recommendations. The
purchase order consists of 75,000
proBEAT glucose sensors over
an initial five-month period and
is valued at $500,000 in revenue.
HealthFleet has an option to
increase volumes based on
customer response.
Restore Health
HealthFleet's RestoreHealth
programme is a corporate,
comprehensive, end-to-end 'wellness
solutio'n offered to subscriber
employees. The programme
delivers high engagement - which
is deemed critical to demonstrable
and sustained health outcomes
-- through unique and extensive
coaching, rich and targeted content
and curriculum, and detailed
reporting across multiple chronic
conditions. HealthFleet has a readymade market
through direct access
to a customer base of several million
employees, consumers, and patients
through its existing client network
and plans to rapidly expand this
further. HealthFleet's customers
include a number of Fortune
500 companies, insurers, and
provider groups.
Members using the RestoreHealth
program for 12 months have
demonstrated positive health
results, including a 5.1% average
weight loss, a significant decrease
in HbA1c -- a key measure of
average blood glucose levels --
and meaningful improvements in
cholesterol and blood pressure
levels. The collaboration between
Nemaura and HealthFleet creates
a potentially compelling new
programme offering that uniquely
positions the RestoreHealth
program in the market. HealthFleet
expects incremental health
benefits by integrating Nemaura's
proBEAT technology into its
RestoreHealth program.
Insulin dose advice
Nemaura Medical has announced
that it now includes insulin under
its DuoPack commercial license
agreement in the US.
Nemaura Medical entered
into a commercial agreement
in September 2021 with
MySugarWatch DuoPack Limited
(MSWDL), under which Nemaura's
non-invasive, wearable skin
patch sensors are paired with
prescription-only medicines for
Type 2 diabetes. This combination
of sensors and medicine aims to
provide a 'one-stop shop' supported
by a holistic care approach.
The inclusion of insulin in its
agreement with MSWDL means
patients with Type 2 diabetes
will have access to a CGMguided
insulin dose titration care
model that is designed to reduce
hypoglycemic episodes and hospital
admissions while improving
long-term outcomes," said CEO
Chowdhury, "Moreover, it uniquely
avoids a potentially bruised, slowto-heal,
infection-prone, needleinduced
skin puncture wound in
older patients at the site of a CGM
sensor skin application."
*The body mass index (BMI) is a
measure that uses your height and
weight to work out if your weight is
healthy. The BMI calculation divides
an adult's weight in kilograms by
their height in metres squared. For
example, A BMI of 25 means 25kg/m2.
For most adults, an ideal BMI is in the
18.5 to 24.9 range.
www.nemaura.co.uk
More on Miboko
Miboko integrates Nemaura's
non-invasive sensor with a
diet and wellbeing program to
provide an indication of a person's
metabolic health and wellbeing.
The partnership with the UK's
NHS is through medical centers
that are partnered with the NHS's
National Institute for Health and
Care Research (NIHR) to gather
information that helps change
and save lives. The Practice where
the studies are being undertaken
are certified Research Ready
by the Royal College of General
Practitioners and regularly
undertakes independent studies.
Miboko will be initially
available without prescription
and is recommended for use by
those wishing to lose weight and
improve their general health and
wellbeing. The program will be
relevant to those with prediabetes
as well as to people with obesity.
Significantly, Miboko will also be
used by people who wish to embark
on a diet program, many of whom
will have tried alternative diet plans.
The Company has plans to gather
long-term outcome data that could
potentially support reimbursement.
For too long, good health has
seemed out of reach. Miboko is
doing things differently, apparently,
giving high quality, personalized
health support.
With Miboko, a user gets its
unique, world-first sensor that
sits on your arm and monitors
how your body reacts to food, in
real-time. A sleek smartphone
app helps the user to not only see
what's happening in your body
but understand what it means for
their health. There are also regular
expert recommendations from
our in-house team of nutritionists,
clinical behaviourists, and scientists
to help users to easily adjust their
diet and behaviours to get the most
out of the data the sensor supplies.
www.miboko.com